Review Article
Year: 2020 | Month: January-March | Volume: 5 | Issue: 1 | Pages: 6-11
Chronic Myeloid Leukemia in India: A Review
Namrata Bhutani
Senior Resident, Department of Biochemistry, Vardhaman Mahavir Medical College & Safdarjung Hospital, New Delhi.
ABSTRACT
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. CML is the commonest adult leukaemia in India and the annual incidence ranges from 0.8–2.2/100,000 population in males and 0.6–1.6/100,000 population in females in India. The median age of diagnosis is 38-40 years. Chronic myeloid leukemia is divided into three phases based on clinical characteristics and laboratory findings. CML prognostic scoring systems stratify patients into risk groups based on patient and disease related characteristics at diagnosis . With the introduction of the Tyrosine Kinase Inhibitor, imatinib, the treatment and natural history of CML has changed dramatically in recent years, with an improvement in the 5-year survival rate from little more than 20% to over 90%.This article presents a brief review about chronic myeloid leukemia and its therapy.
Keywords: Chronic myeloid leukemia, CML, pluripotent stem cell, leukaemia in India.